Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYRO3 | Q06418 | 14/20 | 0.66 |
| ▸ | MERTK | Q12866 | 8/20 | 0.59 |
| ▸ | AXL | P30530 | 6/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19398175 | 0.99 | TYRO3 (0.67) | TYRO3MERTKAXL | |
| SCHEMBL19429644 | 0.92 | TYRO3 (0.71) | TYRO3MERTKAXL | |
| SCHEMBL19377575 | 0.89 | TYRO3 (0.75) | TYRO3MERTKAXL | |
| SCHEMBL19398174 | 0.88 | MERTK (0.62) | TYRO3MERTKAXL | |
| SCHEMBL19377721 | 0.88 | MERTK (0.64) | TYRO3MERTKAXL | |
| SCHEMBL19429645 | 0.87 | TYRO3 (0.54) | TYRO3MERTKAXL | |
| SCHEMBL19377752 | 0.83 | MERTK (0.84) | TYRO3MERTKAXL | |
| SCHEMBL19398159 | 0.82 | TYRO3 (0.85) | TYRO3MERTKAXL | |
| SCHEMBL19377511 | 0.82 | TYRO3 (0.69) | TYRO3MERTKAXL | |
| SCHEMBL19377565 | 0.81 | TYRO3 (0.85) | TYRO3MERTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042765-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORP (US) | 2026-02-12 | — | — | US | disclosed |
| US-12415809-B2 | Pyrrolotriazine compounds as tam inhibitors | INCYTE CORPORATION (US) | 2025-09-16 | — | — | US | disclosed |
| CN-114456175-B | Pyrrolotriazine compounds as TAM inhibitors | 因赛特公司 | 2024-09-03 | — | — | CN | disclosed |
| CN-114456176-B | Pyrrolotriazine compounds as TAM inhibitors | 因赛特公司 | 2024-08-30 | — | — | CN | disclosed |
| US-20240124463-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORPORATION | 2024-04-18 | — | — | US | disclosed |
| EP-4321513-A2 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | Incyte Corporation (US) | 2024-02-14 | — | — | EP | disclosed |
| EP-3436461-B1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORP (US) | 2023-11-01 | — | — | EP | disclosed |
| US-11591338-B2 | Pyrrolotriazine compounds as TAM inhibitors | INCYTE CORPORATION (US) | 2023-02-28 | — | — | US | disclosed |
| US-20210147430-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORPORATION | 2021-05-20 | — | — | US | disclosed |
| US-10844069-B2 | Pyrrolotriazine compounds as TAM inhibitors | INCYTE CORPORATION (US) | 2020-11-24 | — | — | US | disclosed |
| US-20200131185-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORPORATION | 2020-04-30 | — | — | US | disclosed |
| US-10442810-B2 | Pyrrolotriazine compounds as TAM inhibitors | INCYTE CORPORATION (US) | 2019-10-15 | — | — | US | disclosed |
| US-20180327412-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORPORATION | 2018-11-15 | — | — | US | disclosed |
| US-9981975-B2 | Pyrrolotriazine compounds as tam inhibitors | INCYTE CORPORATION (US) | 2018-05-29 | — | — | US | disclosed |
| US-20170275290-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORPORATION | 2017-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260042765-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | MAP2K2, TTK, MAP2K5 | TYRO3 96/4885MERTK 16/4885AXL 107/4885 |
| US-20210147430-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | MERTK, MAP3K15, MAP3K5 | TYRO3 106/4885MERTK 1/4885AXL 49/4885 |
| US-20180327412-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | MERTK, MAP3K15, MAP3K5 | TYRO3 106/4885MERTK 1/4885AXL 49/4885 |
| US-10844069-B2 | Pyrrolotriazine compounds as TAM inhibitors | MERTK, MAP3K15, MAP3K5 | TYRO3 106/4885MERTK 1/4885AXL 49/4885 |
| US-20170275290-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | MERTK, MAP3K15, MAP3K5 | TYRO3 106/4885MERTK 1/4885AXL 49/4885 |
| US-20200131185-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | MERTK, MAP3K15, MAP3K5 | TYRO3 106/4885MERTK 1/4885AXL 49/4885 |
| US-10442810-B2 | Pyrrolotriazine compounds as TAM inhibitors | MERTK, MAP3K15, MAP3K5 | TYRO3 106/4885MERTK 1/4885AXL 49/4885 |
| US-12415809-B2 | Pyrrolotriazine compounds as tam inhibitors | MERTK, MAP3K15, MAP3K5 | TYRO3 106/4885MERTK 1/4885AXL 49/4885 |
| US-11591338-B2 | Pyrrolotriazine compounds as TAM inhibitors | MERTK, MAP3K15, MAP3K5 | TYRO3 106/4885MERTK 1/4885AXL 49/4885 |
| US-20240124463-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | MERTK, MAP3K15, MAP3K5 | TYRO3 106/4885MERTK 1/4885AXL 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.